A Dose-Finding Study of N-Acetylcysteine (NAC) to Prevent Cisplatin-induced Hearing Loss in Children With Cancer

Trial Profile

A Dose-Finding Study of N-Acetylcysteine (NAC) to Prevent Cisplatin-induced Hearing Loss in Children With Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Acetylcysteine (Primary)
  • Indications Hearing loss
  • Focus Pharmacokinetics
  • Most Recent Events

    • 18 Mar 2016 Planned End Date changed from 1 Aug 2019 to 1 Oct 2019, according to ClinicalTrials.gov record.
    • 18 Mar 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 11 Jan 2016 Planned End Date changed from 1 Mar 2019 to 1 Aug 2019 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top